Insider · CIK 0001814872

Reddoch James F.

Reports to the SEC for 1 company · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001814872

Forms 4 and 5

Insider transactions

36 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2022-09-28	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−100K sh	$41.23	−$4.12M	820,800
2022-08-12	RPRXRoyalty Pharma plc · LP interests in RPI US Partners 2019, LPG Gift	EVP & Chief Scientific Officer	GGift	−2,400 sh	—	—	478,870
2022-06-08	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−100K sh	$41.56	−$4.16M	920,800
2022-05-27	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−75K sh	$41.08	−$3.08M	1,020,800
2022-05-19	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−75K sh	$40.44	−$3.03M	1,095,800
2021-09-10	RPRXRoyalty Pharma plc · LP interests in RPI US Partners 2019, LPG Gift	EVP & Chief Scientific Officer	GGift	−5,128 sh	—	—	481,270
2021-07-26	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−8,949 sh	$39.78	−$356K	1,170,800
2021-07-26	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−8,949 sh	$39.78	−$356K	1,170,800
2021-07-14	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−2 sh	$42.00	−$84	1,179,749
2021-07-13	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−17.8K sh	$42.01	−$749K	1,179,751
2021-07-12	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−100 sh	$42.04	−$4,204	1,197,583
2021-07-08	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−40.7K sh	$42.05	−$1.71M	1,197,683
2021-07-07	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−2,192 sh	$42.01	−$92.1K	1,238,338
2021-07-06	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−30.3K sh	$42.40	−$1.28M	1,240,530
2021-06-08	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−50K sh	$46.43	−$2.32M	1,270,800
2021-06-07	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−47.8K sh	$46.57	−$2.23M	1,323,010
2021-06-07	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−2,210 sh	$47.01	−$104K	1,320,800
2021-06-04	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−100K sh	$44.60	−$4.46M	1,370,800
2021-06-02	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−50K sh	$42.13	−$2.11M	1,470,800
2021-05-07	RPRXRoyalty Pharma plcC Conversion	EVP & Chief Scientific Officer	CConversion	+1.32M sh	—	—	1,520,800
2021-05-07	RPRXRoyalty Pharma plc · LP interests in RPI US Partners 2019, LPC Conversion	EVP & Chief Scientific Officer	CConversion	−132K sh	—	—	486,398
2021-04-14	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−55.7K sh	$42.10	−$2.35M	200,000
2021-04-12	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−359 sh	$42.32	−$15.2K	255,714
2021-03-22	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−43.9K sh	$46.32	−$2.03M	256,073
2021-03-02	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−96.5K sh	$46.89	−$4.52M	303,510
2021-03-02	RPRXRoyalty Pharma plcS Sale	EVP & Chief Scientific Officer	SSale	−3,510 sh	$47.84	−$168K	300,000
2020-12-31	RPRXRoyalty Pharma plcC Conversion	EVP & Chief Scientific Officer	CConversion	+270K sh	—	—	270,100
2020-12-31	RPRXRoyalty Pharma plcC Conversion	EVP & Chief Scientific Officer	CConversion	+130K sh	—	—	400,000
2020-12-31	RPRXRoyalty Pharma plc · LP interests in RPI US Partners 2019, LPC Conversion	EVP & Chief Scientific Officer	CConversion	−27K sh	—	—	2,107
2020-12-31	RPRXRoyalty Pharma plc · LP interests in RPI US Partners 2019, LPC Conversion	EVP & Chief Scientific Officer	CConversion	−13K sh	—	—	618,478
2020-06-18	RPRXRoyalty Pharma plcC Conversion	EVP & Chief Scientific Officer	CConversion	+25K sh	—	—	25,030
2020-06-18	RPRXRoyalty Pharma plc · LP interests in RPI International Holdings 2019, LPC Conversion	EVP & Chief Scientific Officer	CConversion	−2,503 sh	—	—	195
2020-06-15	RPRXRoyalty Pharma plc · LP interests in RPI US Partners 2019, LPA Award	EVP & Chief Scientific Officer	AAward	+29.1K sh	—	—	29,117
2020-06-15	RPRXRoyalty Pharma plc · LP interests in RPI US Partners 2019, LPA Award	EVP & Chief Scientific Officer	AAward	+631K sh	—	—	631,468
2020-06-15	RPRXRoyalty Pharma plc · LP interests in RPI International Holdings 2019, LPA Award	EVP & Chief Scientific Officer	AAward	+2,698 sh	—	—	2,698
2020-06-15	RPRXRoyalty Pharma plc · ICAI InterestsA Award	EVP & Chief Scientific Officer	AAward	+200K sh	—	—	200,000

Recent filings

Accepted (ET)
Sep 304
Reddoch James F.0001209191-22-051637
SEC(opens sec.gov)
Jun 104
Reddoch James F.0000899243-22-021954
SEC(opens sec.gov)
May 314
Reddoch James F.0001209191-22-032906
SEC(opens sec.gov)
May 234
Reddoch James F.0001209191-22-031366
SEC(opens sec.gov)
Dec 304
Reddoch James F.0001209191-21-071636
SEC(opens sec.gov)
Jul 274
Reddoch James F.0001209191-21-048313
SEC(opens sec.gov)
Jul 274
Reddoch James F.0001209191-21-048310
SEC(opens sec.gov)
Jul 144
Reddoch James F.0000899243-21-028334
SEC(opens sec.gov)
Jul 84
Reddoch James F.0000950103-21-010245
SEC(opens sec.gov)
Jun 84
Reddoch James F.0000950103-21-008570
SEC(opens sec.gov)
Jun 44
Reddoch James F.0000950103-21-008457
SEC(opens sec.gov)
May 114
Reddoch James F.0000950103-21-007078
SEC(opens sec.gov)

Companies

Royalty Pharma plcEVP & Chief Scientific OfficerRPRX

Address

C/O ROYALTY PHARMA PLC 110 EAST 59TH STREET

NEW YORK, NY, 10022